BetterLife Pharma (XCNQ:BETR) Debt-to-Equity : -0.07 (As of Oct. 2023)

View and export this data going back to 2017. Start your Free Trial

What is BetterLife Pharma Debt-to-Equity?

BetterLife Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Oct. 2023 was C$0.08 Mil. BetterLife Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Oct. 2023 was C$0.55 Mil. BetterLife Pharma's Total Stockholders Equity for the quarter that ended in Oct. 2023 was C$-9.18 Mil. BetterLife Pharma's debt to equity for the quarter that ended in Oct. 2023 was -0.07.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for BetterLife Pharma's Debt-to-Equity or its related term are showing as below:

XCNQ:BETR' s Debt-to-Equity Range Over the Past 10 Years
Min: -4.41 Med: -0.12 Max: 1.77
Current: -0.07

During the past 13 years, the highest Debt-to-Equity Ratio of BetterLife Pharma was 1.77. The lowest was -4.41. And the median was -0.12.

XCNQ:BETR's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.14 vs XCNQ:BETR: -0.07

BetterLife Pharma Debt-to-Equity Historical Data

The historical data trend for BetterLife Pharma's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BetterLife Pharma Debt-to-Equity Chart

BetterLife Pharma Annual Data

Trend

Jan14

Jan15

Jan16

Jan17

Jan18

Jan19

Jan20

Jan21

Jan22

Jan23

Debt-to-Equity

Get a 7-Day Free Trial

1.50

1.77

-0.15

-0.36

-0.11

BetterLife Pharma Quarterly Data
	Jan19	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23
Debt-to-Equity	Get a 7-Day Free Trial															-0.12	-0.11	-0.12	-0.12	-0.07

Competitive Comparison of BetterLife Pharma's Debt-to-Equity

For the Biotechnology subindustry, BetterLife Pharma's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BetterLife Pharma's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BetterLife Pharma's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where BetterLife Pharma's Debt-to-Equity falls into.

BetterLife Pharma Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

BetterLife Pharma's Debt to Equity Ratio for the fiscal year that ended in Jan. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.747	+	0.44)	/	-10.728
	=	-0.11

BetterLife Pharma's Debt to Equity Ratio for the quarter that ended in Oct. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.08	+	0.55)	/	-9.181
	=	-0.07

BetterLife Pharma (XCNQ:BETR) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

BetterLife Pharma Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of BetterLife Pharma's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

BetterLife Pharma (XCNQ:BETR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BetterLife Pharma Inc (XCNQ:BETR) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

BETRF:USA NPAU:Germany

Address

1275 West 6th Avenue, Suite 300, Vancouver, BC, CAN, V6H 1A6

Website

https://www.abetterlifepharma.com

BetterLife Pharma Inc a biotechnology company, engages in the development and commercialization of psychedelic products for the treatment of mental disorders in Canada, the United States, Australia, and European Union. It is involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections, such as coronavirus disease and human papillomavirus, and/or to directly inhibit tumors to treat various types of cancer.

Executives

Ahmad Doroudian

Director, Senior Officer